ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Acquires Epigenetics Firm

by Lisa M. Jarvis
December 22, 2014 | APPEARED IN VOLUME 92, ISSUE 51

Merck & Co. has bought privately held OncoEthix, which is developing a class of epigenetics-based compounds called bromodomain (BET) inhibitors. Merck will pay up to $110 million up front for the Switzerland-based biotech and could shell out another $265 million in milestone payments. OncoEthix’s lead BET inhibitor, OTX015, which was licensed from Mitsubishi Tanabe Pharma in 2012, is in Phase Ib studies for the treatment of hematological cancers and solid tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment